Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.
調査の概要
状態
条件
詳細な説明
This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:
- Assess LMS patients' beliefs and attitudes about the heritability of LMS.
- Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.
Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.
Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Gregg Wood
- 電話番号:801-646-4215
- メール:gregg.wood@hci.utah.edu
研究場所
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute at the University of Utah
-
コンタクト:
- Wendy K Kohlmann, MS
- 電話番号:801-587-5556
- メール:wendy.kohlmann@hci.utah.edu
-
主任研究者:
- Wendy K Kohlmann, MS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will be Patients with a confirmed or self reported diagnosis of LMS
説明
Inclusion
- Living
- Able to speak and read English or Spanish
- Mentally competent
- Age 18 or older
Exclusion
- <18 years
- Unable to read or write
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Patients with leiomyosarcoma
Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Beliefs about the heritability of Leiomyosarcoma
時間枠:up to 1 day from study enrollment
|
This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental. |
up to 1 day from study enrollment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Interest in germline genetic testing
時間枠:up to 1 day from study enrollment
|
This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions. |
up to 1 day from study enrollment
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preferences for receiving information about genetic testing.
時間枠:up to 1 day from study enrollment
|
This outcome will report the count of participants who self reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically . |
up to 1 day from study enrollment
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Wendy Kohlmann, MS、Huntsman Cancer Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 165523
- 1P50CA272170-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。